Some of the recent strategies aimed toward delaying or reversing drug resistance include extended adjuvant therapy in EBC and the addition of targeted agents, such as CDK4 and 6 inhibitors, in ABC. This evidence concerns the gene CDK4 and aneurysmal bone cyst.